NYSEARCA:CYBN - NYSE Arca - CA23256X4075 - Common Stock - Currency: USD
9.09
-0.24 (-2.57%)
The current stock price of CYBN is 9.09 USD. In the past month the price decreased by -10.79%. In the past year, price decreased by -36.21%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.53 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.62 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.81 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Cybin Inc is a CA-based company operating in Pharmaceuticals industry. The company is headquartered in Toronto, Ontario and currently employs 50 full-time employees. The company went IPO on 2018-01-05. Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The firm creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The firm is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. The company has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The firm operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
CYBIN INC
100 King Street West, Suite 5600
TORONTO ONTARIO CA
CEO: Doug Drysdale
Employees: 50
Company Website: https://www.cybin.com
Investor Relations: http://ir.cybin.com/overview/default.aspx
Phone: 19087648385
The current stock price of CYBN is 9.09 USD. The price decreased by -2.57% in the last trading session.
The exchange symbol of CYBIN INC is CYBN and it is listed on the NYSE Arca exchange.
CYBN stock is listed on the NYSE Arca exchange.
CYBIN INC (CYBN) has a market capitalization of 181.80M USD. This makes CYBN a Micro Cap stock.
CYBIN INC (CYBN) currently has 50 employees.
CYBIN INC (CYBN) has a support level at 8.88 and a resistance level at 9.13. Check the full technical report for a detailed analysis of CYBN support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
CYBN does not pay a dividend.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 83% to CYBN. The Buy consensus is the average rating of analysts ratings from 7 analysts.